Inflammatory Bowel Disease Longitudinal Care - USMLE Step 3

SECTION 1

Historical Context & Motivation for Longitudinal IBD Management

The recognition of inflammatory bowel disease (IBD) as a chronic, relapsing-remitting condition requiring sustained management rather than episodic treatment has fundamentally reshaped how gastroenterologists approach patient care. For much of the twentieth century, physicians treated flares reactively with corticosteroids and sulfasalazine, then discharged patients until the next crisis. The introduction of immunomodulators, biologic agents, and a "treat-to-target" philosophy has moved the field toward proactive, longitudinal care that aims to prevent irreversible bowel damage, reduce hospitalizations, and lower cancer risk. Understanding this evolution is essential for any physician managing IBD in the ambulatory setting, a scenario frequently tested on USMLE Step 3.

1932 • Crohn, Ginzburg, and Oppenheimer Describe Regional Ileitis

Burrill Crohn and colleagues published the landmark description of terminal ileitis as a distinct granulomatous disease, distinguishing it from intestinal tuberculosis and establishing the foundation for what would become Crohn's disease.

1955 • Truelove & Witts Trial of Cortisone in Ulcerative Colitis

This randomized trial in the British Medical Journal proved that cortisone could induce remission in ulcerative colitis, introducing corticosteroids as the first evidence-based treatment for IBD flares.

1995 • Azathioprine Established as Steroid-Sparing Maintenance Therapy

Landmark meta-analyses confirmed that thiopurines (azathioprine, 6-mercaptopurine) were effective for maintaining remission in both Crohn's disease and ulcerative colitis, shifting the paradigm toward sustained immunosuppression.

1998 • Infliximab Approved for Crohn's Disease

The ACCENT trials demonstrated that infliximab, an anti-TNF-α monoclonal antibody, induced and maintained remission and enabled mucosal healing — ushering in the biologic era of IBD management.

2015–Present • Treat-to-Target and Tight Control Strategies

The CALM and STRIDE trials formalized a proactive strategy using objective biomarkers (fecal calprotectin, C-reactive protein) and endoscopic endpoints to guide therapy escalation, establishing the modern framework for longitudinal IBD care.

The central question that drove this transformation remains clinically relevant today: how can we shift from merely suppressing symptoms during acute flares to preventing progressive bowel damage through continuous, evidence-based outpatient management? The sections that follow address this question by examining core principles, therapeutic algorithms, surveillance strategies, and the management of long-term complications.

SECTION 2

Core Principles of Longitudinal IBD Care

Effective longitudinal IBD management rests on several interlocking principles that the USMLE Step 3 expects candidates to understand and apply in clinical vignettes. These principles guide therapeutic decisions from the moment of diagnosis through decades of follow-up, encompassing drug selection, monitoring, cancer surveillance, and complication prevention.

Treat-to-Target

Therapy is escalated based on objective endpoints — mucosal healing on endoscopy, normalization of CRP, and fecal calprotectin < 150–250 µg/g — rather than symptom relief alone.

Step-Up vs. Top-Down Therapy

Traditional step-up approaches begin with aminosalicylates and escalate to immunomodulators then biologics. High-risk patients (young age, deep ulceration, perianal disease) may warrant early biologic initiation (top-down) to prevent complications.

Steroid-Free Remission

Corticosteroids are effective for inducing remission but must never be used as long-term maintenance therapy. The goal is steroid-free clinical and endoscopic remission sustained by appropriate maintenance agents.

Colorectal Cancer Surveillance

Patients with colonic IBD require surveillance colonoscopy beginning 8 years after symptom onset, typically repeated every 1–3 years with chromoendoscopy or high-definition white light and targeted biopsies.

Immunization & Infection Prophylaxis

Before initiating immunosuppressive therapy, clinicians must verify vaccination status (especially hepatitis B, varicella, influenza, pneumococcal, and HPV), screen for latent tuberculosis, and check hepatitis B serologies to prevent reactivation syndromes.

✦

KEY TAKEAWAY

Think of longitudinal IBD care like maintaining an aircraft: you do not wait for engine failure (a severe flare or stricture) before performing maintenance. Instead, you follow a scheduled inspection protocol — regular labs, biomarkers, and endoscopies — and perform targeted repairs (therapy adjustments) based on what those inspections reveal, not merely on whether the pilot reports turbulence (symptoms). The treat-to-target approach ensures the disease stays in deep remission rather than merely symptom-free.

SECTION 3

Therapeutic Algorithm — Visual Overview

The following diagram illustrates a simplified therapeutic algorithm for the longitudinal management of moderate-to-severe IBD. It outlines the decision pathway from initial diagnosis through induction therapy, maintenance therapy, and the monitoring checkpoints that guide escalation or de-escalation. This flowchart is designed to reflect current AGA and ACG guideline recommendations and the clinical reasoning tested on USMLE Step 3.

This algorithm shows the two major pathways — step-up (left, low-risk) and top-down (right, high-risk) — converging on a shared monitoring loop. Treat-to-target monitoring with CRP, fecal calprotectin, and endoscopy determines whether therapy is maintained or escalated. Note the CRC surveillance arm beginning at year 8 of disease.

Several features of this algorithm merit emphasis. First, the pre-treatment workup (vaccination, tuberculosis screening, hepatitis B serologies) must precede immunosuppressive therapy to avoid potentially fatal reactivation infections. Second, risk stratification at diagnosis — considering factors such as age under 30, extensive or deep ulceration, perianal disease, and need for steroids at presentation — determines whether a patient enters the step-up or top-down pathway. Third, the monitoring loop is continuous; even patients who achieve remission remain in regular follow-up with labs and periodic endoscopy. Finally, therapeutic drug monitoring (TDM) is increasingly used to distinguish between inadequate drug levels (pharmacokinetic failure, addressable by dose optimization) and adequate levels with persistent disease activity (mechanistic failure, requiring a class switch).

SECTION 4

Pharmacologic Mechanisms & Therapeutic Drug Monitoring

Longitudinal IBD care depends on understanding the pharmacologic mechanisms and monitoring parameters of the major drug classes used for maintenance therapy. The USMLE Step 3 frequently tests candidates on when to initiate, when to escalate, and how to monitor these agents.

Aminosalicylates (5-ASA)

Mesalamine and its derivatives act locally on the colonic mucosa through inhibition of cyclooxygenase and lipoxygenase pathways, reduction of NF-κB activation, and scavenging of reactive oxygen species. They are the cornerstone of mild-to-moderate ulcerative colitis induction and maintenance but have limited efficacy in Crohn's disease. Monitoring includes annual renal function testing (BUN, creatinine) because of the rare risk of tubulointerstitial nephritis.

Thiopurines (Azathioprine, 6-Mercaptopurine)

Thiopurines are purine analogs that inhibit de novo nucleotide synthesis and induce T-cell apoptosis. Before starting therapy, thiopurine S-methyltransferase (TPMT) or NUDT15 genotype/enzyme activity must be checked. Patients with low or absent TPMT activity are at markedly increased risk for severe myelosuppression. Regular monitoring includes CBC with differential every 1–3 months and hepatic function panels. Thiopurine metabolite levels (6-thioguanine nucleotides [6-TGN] and 6-methylmercaptopurine [6-MMP]) guide dose optimization: a target 6-TGN level of 235–450 pmol/8 × 10⁸ RBCs correlates with therapeutic efficacy.

Anti-TNF-α Biologics

Infliximab, adalimumab, certolizumab pegol, and golimumab target tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine central to IBD pathogenesis. These agents induce and maintain remission, promote mucosal healing, and reduce the need for surgery and hospitalizations. Therapeutic drug monitoring (TDM) is now standard: trough drug levels and anti-drug antibody (ADA) titers are measured to differentiate pharmacokinetic failure from mechanistic failure. For infliximab, target trough levels are generally ≥ 5 µg/mL during maintenance. If the trough is low with no ADAs, increasing the dose or shortening the interval is appropriate. If ADAs are present and the drug level is undetectable, switching to another anti-TNF or a different mechanism is recommended.

Newer Mechanisms: Anti-Integrins, Anti-IL-12/23, and JAK Inhibitors

Vedolizumab, a gut-selective anti-α4β7 integrin antibody, reduces lymphocyte trafficking to the GI tract and is favored in patients at higher infection risk because of its limited systemic immunosuppression. Ustekinumab targets the p40 subunit shared by IL-12 and IL-23, blocking Th1 and Th17 inflammatory pathways. Tofacitinib and upadacitinib are oral JAK inhibitors approved for ulcerative colitis; they carry specific warnings for thromboembolic events, herpes zoster reactivation, and cardiovascular risk, necessitating careful patient selection and monitoring. Understanding the side effect profiles of these agents is essential for USMLE Step 3 vignettes in which a patient fails first-line therapy and requires a therapeutic switch.

⚠

High-Yield for USMLE Step 3

Before starting any biologic or immunomodulator, complete the following pre-treatment checklist: (1) Screen for latent TB with PPD or IGRA, (2) Check hepatitis B surface antigen, surface antibody, and core antibody, (3) Update vaccinations — live vaccines are contraindicated once immunosuppression begins, (4) Check TPMT/NUDT15 if starting thiopurines. Failure to screen for latent TB before anti-TNF therapy is a classic exam trap.

SECTION 5

Surveillance & Complication Prevention

Beyond pharmacotherapy, longitudinal IBD care involves structured screening for malignancy, metabolic bone disease, nutritional deficiencies, and extraintestinal manifestations. This section details the surveillance schedule and the classification of IBD-associated complications, which are tested frequently on USMLE Step 3.

This surveillance schedule summarizes the recommended screening intervals for the major long-term complications of IBD and its treatments. Note that CRC surveillance begins 8 years after symptom onset (not diagnosis), and patients with concurrent primary sclerosing cholangitis (PSC) should undergo annual colonoscopy from the time of PSC diagnosis because of their markedly elevated CRC risk.

Extraintestinal Manifestations — High-Yield Classification

Category	Parallels Disease Activity	Independent of Disease Activity
Dermatologic	Erythema nodosum	Pyoderma gangrenosum
Ophthalmologic	Episcleritis	Uveitis (may be independent)
Musculoskeletal	Peripheral (type 1) arthritis	Ankylosing spondylitis, sacroiliitis
Hepatobiliary	Hepatic steatosis (steroid-related)	Primary sclerosing cholangitis
Hematologic	Iron deficiency anemia	Venous thromboembolism (↑ risk even in remission)

Extraintestinal manifestations of IBD classified by association with disease activity

A clinically important distinction is that manifestations paralleling disease activity (erythema nodosum, episcleritis, peripheral arthritis) typically improve when bowel inflammation is treated, whereas manifestations independent of disease activity (PSC, ankylosing spondylitis, pyoderma gangrenosum) require targeted management regardless of the intestinal disease state. Venous thromboembolism deserves special mention: IBD patients have a 2–3× increased risk of VTE, and prophylaxis during hospitalization is strongly recommended.

SECTION 6

Worked Clinical Vignette — Longitudinal IBD Management

The following worked example simulates a USMLE Step 3 clinical vignette that tests multiple dimensions of longitudinal IBD care, including treatment escalation, therapeutic drug monitoring, and surveillance colonoscopy.

Clinical Vignette: 28-Year-Old with Crohn's Disease on Infliximab

1
Step 1 — Read the Stem and Identify Key Clinical Data

A 28-year-old woman with ileocolonic Crohn's disease diagnosed 3 years ago presents for follow-up. She was initially started on infliximab and azathioprine after presenting with deep ileal ulcers. She reports mild abdominal cramping over the past 2 months. Labs: CRP 18 mg/L (normal < 5), fecal calprotectin 480 µg/g (target < 150–250). Her infliximab trough level is 2.1 µg/mL (target ≥ 5 µg/mL), and anti-drug antibodies are undetectable. TPMT genotype is normal. Her last colonoscopy 1 year ago showed mucosal healing. She is up to date on vaccinations.

Key findings: subtherapeutic infliximab trough, elevated inflammatory markers, no anti-drug antibodies.
2
Step 2 — Interpret the Therapeutic Drug Monitoring Results

The infliximab trough of 2.1 µg/mL is below the recommended ≥ 5 µg/mL, indicating pharmacokinetic failure. Critically, anti-drug antibodies (ADAs) are absent. This is significant: if high ADAs were present, switching to a different biologic would be necessary. Because the drug level is simply low without immunogenicity, the correct strategy is dose optimization — either increasing the dose from 5 mg/kg to 10 mg/kg or shortening the infusion interval from every 8 weeks to every 6 weeks.

Diagnosis: Pharmacokinetic failure (low trough, no ADAs) → Dose escalation indicated.
3
Step 3 — Apply the Treat-to-Target Framework

Despite mild symptoms, the elevated CRP and calprotectin indicate ongoing subclinical inflammation. In a treat-to-target model, the objective biomarkers — not the patient's mild symptoms — drive the treatment decision. This patient has not met her targets (CRP < 5, calprotectin < 150–250, mucosal healing), so therapy must be optimized. The question may present distractors such as 'reassure and continue current regimen' or 'switch to vedolizumab.' Reassurance is incorrect because targets are not met, and switching mechanism is premature without evidence of mechanistic failure or immunogenicity.

Best answer: Increase infliximab dose or shorten interval (dose optimization).
4
Step 4 — Address Ongoing Surveillance Needs

Although the primary question asks about treatment escalation, the vignette also tests surveillance knowledge. This patient has had Crohn's disease for 3 years, which means CRC surveillance colonoscopy is not yet due (recommended starting 8 years after symptom onset for colonic disease). However, given the rising biomarkers, a colonoscopy may be indicated sooner to assess for endoscopic evidence of relapse and guide further management decisions. Her azathioprine should be continued as part of combination therapy to reduce immunogenicity, and she should continue annual dermatologic exams given thiopurine-associated non-melanoma skin cancer risk.

CRC screening not yet due, but consider repeat colonoscopy to reassess disease activity. Continue combination therapy and annual skin cancer screening.
5
Step 5 — Synthesize the Final Management Plan

The complete management plan for this patient includes: (1) Optimize infliximab — increase dose to 10 mg/kg or shorten interval to every 6 weeks; (2) Recheck trough level, CRP, and calprotectin in 8–12 weeks to confirm improvement; (3) Consider repeat colonoscopy in 3–6 months to evaluate for mucosal healing; (4) Continue azathioprine for synergy and immunogenicity prevention; (5) Maintain vaccination schedule and annual dermatologic screening.

Final Answer: Dose-optimize infliximab (pharmacokinetic failure without immunogenicity), recheck biomarkers, and maintain surveillance schedule.

SECTION 7

Crohn's Disease vs. Ulcerative Colitis — Longitudinal Differences

Although Crohn's disease and ulcerative colitis share the IBD umbrella, their longitudinal management strategies diverge substantially. The following comparison highlights the key differences tested on USMLE Step 3, from pharmacologic choices to surgical considerations and surveillance nuances.

Feature	Crohn's Disease	Ulcerative Colitis
5-ASA role	Limited; not recommended for maintenance	Cornerstone of mild-moderate induction and maintenance (oral + topical)
Methotrexate	Effective steroid-sparing agent (IM preferred)	No proven efficacy; not recommended
Surgical cure	No curative surgery; resection for complications only (stricture, fistula, abscess)	Total proctocolectomy with IPAA is curative (but pouchitis may occur)
Post-surgical prophylaxis	Post-resection prophylaxis (often anti-TNF or thiopurine); colonoscopy at 6–12 months	Pouchoscopy annually; antibiotics for pouchitis
Perianal disease	Common; fistulae require combined surgical + medical (anti-TNF) management	Rare; if present, reconsider Crohn's diagnosis
B12 deficiency risk	Yes — terminal ileal disease or resection impairs B12 absorption	Rare unless extensive backwash ileitis or post-colectomy
JAK inhibitors (tofacitinib)	Not currently approved (trials ongoing)	Approved for moderate-severe UC refractory to biologics

Key longitudinal management differences between Crohn's disease and ulcerative colitis

✦

KEY TAKEAWAY

Think of Crohn's and UC as two different roads through the same landscape. UC is like a highway with a clear start (rectum) and end (proximal extent) — and because the disease is limited to the mucosal surface and colon, removing the highway (total proctocolectomy) is curative. Crohn's disease, in contrast, is like a network of back roads that can pop up anywhere from mouth to anus and burrow through the full bowel wall; you can patch individual sections (resection), but new roads may appear, making medical maintenance indispensable even after surgery.

SECTION 8

Pregnancy, Special Populations, and Emerging Therapies

USMLE Step 3 emphasizes the management of chronic diseases in the context of pregnancy and other special situations. IBD longitudinal care intersects with several advanced topics, including preconception counseling, medication safety during pregnancy and lactation, geriatric considerations, and newer therapeutic approaches that are increasingly entering clinical practice.

Medication	Safe in Pregnancy?	Key Notes
Mesalamine (5-ASA)	Yes — low risk	Continue throughout pregnancy. Avoid formulations containing dibutyl phthalate (rare).
Thiopurines (AZA/6-MP)	Yes — generally continued	Benefits of maintaining remission outweigh theoretical risks. Monitor neonatal CBC.
Anti-TNF agents	Yes — low risk	Consider stopping in third trimester to limit transplacental transfer. Avoid live vaccines in infant for 6–12 months.
Methotrexate	CONTRAINDICATED	Teratogenic (category X). Discontinue ≥ 3 months before conception in both men and women. Provide folate supplementation.
Tofacitinib (JAK inhibitor)	CONTRAINDICATED	Animal data show teratogenicity. Discontinue before conception. Use effective contraception during therapy.
Vedolizumab	Likely safe — limited data	Gut-selective mechanism suggests lower systemic immunosuppression. Shared decision-making recommended.

IBD medication safety in pregnancy — high yield for USMLE Step 3

The most important principle in IBD and pregnancy is that active disease poses a greater risk to the fetus than most IBD medications. Flares during pregnancy increase the risk of preterm delivery, low birth weight, and spontaneous abortion. Therefore, maintaining remission with safe agents is the priority. Methotrexate and JAK inhibitors must be discontinued well before conception, but aminosalicylates, thiopurines, and anti-TNF agents are generally continued throughout pregnancy.

Emerging Therapeutic Frontiers

Several newer agents and strategies are reshaping how longitudinal IBD care will be delivered in the coming decade. Risankizumab and guselkumab, selective anti-IL-23 p19 antibodies, have shown efficacy in Crohn's disease and may offer improved selectivity over ustekinumab. Ozanimod, a sphingosine-1-phosphate receptor modulator, is approved for UC and functions by trapping lymphocytes in lymph nodes, reducing gut-homing immune cells. Additionally, combination biologic therapy ("dual biologic" strategies pairing vedolizumab with an anti-TNF or ustekinumab) is being explored for refractory patients, although evidence remains limited and infectious risk monitoring is critical. While these agents are unlikely to be tested in detail on current exams, familiarity with their mechanisms positions clinicians for the evolving standard of care.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 35-year-old man with ulcerative colitis has been on prednisone 40 mg daily for 6 months for persistent symptoms. His physician wishes to transition him to a steroid-sparing maintenance regimen. Which of the following is the most critical reason that long-term corticosteroid maintenance is avoided in IBD?

Show answer

Long-term corticosteroids do not maintain remission in IBD (high relapse rate upon taper) and carry serious cumulative side effects including osteoporosis, adrenal suppression, glucose intolerance, cataracts, opportunistic infections, and avascular necrosis. The treat-to-target paradigm mandates steroid-free remission achieved with appropriate maintenance agents such as thiopurines, methotrexate, or biologic therapies. Importantly, steroids do not promote mucosal healing, meaning they leave the patient at risk for disease progression despite symptomatic improvement.

Question 2: BASIC CALCULATION

A patient with Crohn's disease on azathioprine has a 6-thioguanine nucleotide (6-TGN) level of 180 pmol/8 × 10⁸ RBCs and 6-methylmercaptopurine (6-MMP) of 2,500 pmol/8 × 10⁸ RBCs. The target 6-TGN is 235–450 and 6-MMP should be < 5,700. What does this metabolite profile suggest, and what is the appropriate intervention?

Show answer

This metabolite profile shows a subtherapeutic 6-TGN (180, below the 235–450 target) with an elevated 6-MMP, suggesting that the patient is preferentially shunting drug metabolism toward methylation rather than toward the active 6-TGN metabolite. The appropriate intervention is to add allopurinol at a low dose (100 mg) while reducing the thiopurine dose by approximately 25–33%. Allopurinol inhibits xanthine oxidase and redirects metabolism toward 6-TGN production, improving efficacy while lowering the hepatotoxic 6-MMP level. Close monitoring with CBC is essential after this adjustment.

Question 3: INTERMEDIATE

A 42-year-old woman with pancolonic ulcerative colitis diagnosed 10 years ago presents for follow-up. She has been in clinical remission on mesalamine. She has never had a surveillance colonoscopy. She also has concurrent primary sclerosing cholangitis (PSC) diagnosed 2 years ago. What is the appropriate surveillance colonoscopy recommendation for this patient?

Show answer

This patient has two independent indications for surveillance colonoscopy. First, based on UC duration alone, she should have begun CRC surveillance 8 years after symptom onset (she is now 2 years overdue for her first screening). Second, her concurrent PSC places her in the highest risk category for colorectal cancer among IBD patients. Current guidelines recommend that patients with both UC and PSC undergo annual surveillance colonoscopy from the time of PSC diagnosis — meaning she should have begun annual screening 2 years ago. She needs immediate surveillance colonoscopy with chromoendoscopy or high-definition white light with random and targeted biopsies, and this should be repeated annually. Additionally, she should be screened for cholangiocarcinoma with annual liver imaging and CA 19-9.

Question 4: APPLIED

A 29-year-old woman with ileocolonic Crohn's disease on infliximab and azathioprine in remission wishes to become pregnant. Her last colonoscopy showed mucosal healing. Current medications include infliximab 5 mg/kg every 8 weeks, azathioprine 150 mg daily, calcium/vitamin D, and a prenatal vitamin. How should her IBD medications be managed periconceptionally and during pregnancy?

Show answer

The most important principle is that active IBD poses greater fetal risk than maintaining therapy. Both infliximab and azathioprine are considered compatible with pregnancy and should be continued to maintain remission. Infliximab may be considered for dose timing in the third trimester — some clinicians time the last dose so that the trough falls near delivery to minimize transplacental transfer, but the decision must balance the risk of maternal flare. If infliximab is continued into the third trimester, live vaccines (rotavirus, BCG) should be deferred in the infant until 6–12 months of age or until the drug is undetectable in the infant's serum. Azathioprine is continued throughout pregnancy; neonatal CBC is checked after delivery to screen for cytopenias. Methotrexate and JAK inhibitors are absolutely contraindicated and must be stopped at least 3 months before conception. Folic acid supplementation should be ensured. Delivery mode is based on obstetric indications unless active perianal disease is present, in which case cesarean section is preferred.

Question 5: CRITICAL THINKING

A 55-year-old man with Crohn's disease has failed infliximab (high anti-drug antibodies, undetectable drug level) and adalimumab (initial response, then secondary loss of response with adequate trough levels and no ADAs). He continues to have active ileocolonic inflammation on recent colonoscopy. His physician is considering vedolizumab versus ustekinumab versus tofacitinib. Discuss the rationale for choosing between these agents, including mechanism-specific advantages and monitoring considerations.

Show answer

This patient has failed two anti-TNF agents through two different mechanisms: immunogenicity-mediated failure with infliximab (high ADAs, no drug) and mechanistic failure with adalimumab (adequate levels but persistent inflammation), indicating TNF-α may no longer be the primary driver of his disease. A class switch is mandatory. Vedolizumab (anti-α4β7 integrin) is gut-selective and has an excellent safety profile with lower systemic immunosuppression, making it attractive in an older patient; however, its onset of action can be slower, and efficacy data for Crohn's disease are less robust than for UC. Ustekinumab (anti-IL-12/23 p40) has strong Crohn's data, rapid onset, and a favorable safety profile; it is often preferred after anti-TNF failure in Crohn's. Tofacitinib is currently not approved for Crohn's disease (only UC), and it carries risks of thromboembolic events, herpes zoster, and cardiovascular events — particularly concerning in a 55-year-old male. Therefore, ustekinumab would likely be the best choice given its mechanism targeting the IL-12/23 pathway, strong Crohn's efficacy data, and safety profile. Monitoring would include periodic CRP and fecal calprotectin, endoscopic reassessment at 6–12 months, tuberculosis awareness, and standard immunosuppression precautions.

SUMMARY

Inflammatory Bowel Disease Longitudinal Care — Summary

Summary

Longitudinal IBD management requires a proactive, structured approach built on the treat-to-target framework, which uses objective biomarkers — CRP, fecal calprotectin, and endoscopic mucosal healing — rather than symptoms alone to guide therapy. Patients are risk-stratified at diagnosis into step-up or top-down pathways. The overarching goal is steroid-free deep remission maintained by immunomodulators (thiopurines, methotrexate) or biologics (anti-TNF, vedolizumab, ustekinumab), with therapeutic drug monitoring distinguishing pharmacokinetic from mechanistic failure to guide dose optimization or class switching.

Beyond pharmacotherapy, longitudinal care encompasses a comprehensive surveillance schedule: CRC screening beginning 8 years after symptom onset (annually if concurrent PSC), bone density monitoring after steroid exposure, nutritional labs (B12, iron, vitamin D), vaccination updates (no live vaccines on immunosuppression), and annual skin cancer screening for patients on thiopurines. In pregnancy, most IBD medications (5-ASA, thiopurines, anti-TNF) are continued, but methotrexate and JAK inhibitors are absolutely contraindicated. Mastery of these principles — from pretreatment screening through lifelong surveillance — is essential for USMLE Step 3 success.